NASDAQ:PTX - Pernix Therapeutics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$0.08 -0.01 (-11.76 %)
(As of 03/22/2019 04:00 PM ET)
Previous Close$0.0850
Today's Range$0.0670 - $0.0890
52-Week Range$0.20 - $3.30
Volume106,735 shs
Average Volume3.04 million shs
Market Capitalization$1.09 million
P/E RatioN/A
Dividend YieldN/A
Beta1.2
Pernix Therapeutics Holdings, Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription drugs primarily for the United States market. It targets underserved therapeutic areas, such as central nervous system (CNS), including pain, neurology, and psychiatry. The company's products comprise Zohydro ER with BeadTek, an opioid agonist indicated for the management of pain; Silenor, a non-narcotic, non-scheduled, and non-addictive prescription sleep aid for the treatment of insomnia characterized by difficulty with sleep maintenance; and Treximet, a fixed dose combination product indicated for the treatment of acute migraine. Pernix Therapeutics Holdings, Inc. markets and sells its non-core products, including generics through its wholly owned subsidiaries; and markets its non-promoted products through distributors and trade partners. It serves drug wholesalers, specialty pharmacies, retail drug stores, mass merchandisers, and grocery store pharmacies. Pernix Therapeutics Holdings, Inc. was founded in 1996 and is headquartered in Morristown, New Jersey.

Receive PTX News and Ratings via Email

Sign-up to receive the latest news and ratings for PTX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Current SymbolNASDAQ:PTX
CUSIP71426V10
Phone800-793-2145

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$146.07 million
Book Value($14.77) per share

Profitability

Net Income$-77,140,000.00

Miscellaneous

EmployeesN/A
Market Cap$1.09 million
Next Earnings DateN/A
OptionableOptionable

Pernix Therapeutics (NASDAQ:PTX) Frequently Asked Questions

What is Pernix Therapeutics' stock symbol?

Pernix Therapeutics trades on the NASDAQ under the ticker symbol "PTX."

Has Pernix Therapeutics been receiving favorable news coverage?

News coverage about PTX stock has trended positive this week, InfoTrie Sentiment reports. The research group rates the sentiment of news coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Pernix Therapeutics earned a news impact score of 2.2 on InfoTrie's scale. They also gave media coverage about the specialty pharmaceutical company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the immediate future.

Who are some of Pernix Therapeutics' key competitors?

What other stocks do shareholders of Pernix Therapeutics own?

Who are Pernix Therapeutics' key executives?

Pernix Therapeutics' management team includes the folowing people:
  • Mr. John Anthony Sedor, Chairman & CEO (Age 74)
  • Mr. Kenneth R. Pina Esq., Sr. VP, Chief Legal & Compliance Officer and Corp. Sec. (Age 60)
  • Mr. Glenn Whaley, VP of Fin., Principal Financial & Accounting Officer (Age 51)
  • Mr. Anthony M. Orrico, VP of Technical & Supply Operations
  • Mr. George P. Jones, VP of Sales & Marketing

Who are Pernix Therapeutics' major shareholders?

Pernix Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Aisling Capital LLC (17.23%), Geode Capital Management LLC (0.88%) and Barclays PLC (0.48%). View Institutional Ownership Trends for Pernix Therapeutics.

Which institutional investors are selling Pernix Therapeutics stock?

PTX stock was sold by a variety of institutional investors in the last quarter, including Aisling Capital LLC. View Insider Buying and Selling for Pernix Therapeutics.

Which institutional investors are buying Pernix Therapeutics stock?

PTX stock was purchased by a variety of institutional investors in the last quarter, including Geode Capital Management LLC and Barclays PLC. View Insider Buying and Selling for Pernix Therapeutics.

How do I buy shares of Pernix Therapeutics?

Shares of PTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Pernix Therapeutics' stock price today?

One share of PTX stock can currently be purchased for approximately $0.0750.

How big of a company is Pernix Therapeutics?

Pernix Therapeutics has a market capitalization of $1.09 million and generates $146.07 million in revenue each year.

What is Pernix Therapeutics' official website?

The official website for Pernix Therapeutics is http://www.pernixtx.com.

How can I contact Pernix Therapeutics?

Pernix Therapeutics' mailing address is 10 NORTH PARK PLACE SUITE 201, MORRISTOWN NJ, 07960. The specialty pharmaceutical company can be reached via phone at 800-793-2145 or via email at [email protected]


MarketBeat Community Rating for Pernix Therapeutics (NASDAQ PTX)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  329 (Vote Outperform)
Underperform Votes:  219 (Vote Underperform)
Total Votes:  548
MarketBeat's community ratings are surveys of what our community members think about Pernix Therapeutics and other stocks. Vote "Outperform" if you believe PTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PTX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/22/2019 by MarketBeat.com Staff

Featured Article: Quiet Period Expirations

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel